Robert A. Lyon

Effects of Selective Matrix Metalloproteinase Inhibitor (PG-116800) to Prevent Ventricular Remodeling After Myocardial Infarction

Michael Hudson, Paul W. Armstrong, José M. Brum et al. · Journal of the American College of Cardiology · 2006 · 210 citations

Medicine, Cardiology, Pharmacology +15

Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study

Piotr Krzeski, Chris Buckland‐Wright, Géza Bálint et al. · Arthritis Research & Therapy · 2007 · 203 citations · Full text

Medicine, Orthopaedic Surgery, Pharmacology +9

NAN-190: an arylpiperazine analog that antagonizes the stimulus effects of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT)

Richard A. Glennon, Noreen Naiman, M. Edward Pierson et al. · European Journal of Pharmacology · 1988 · 183 citations

Medicine, Medicinal Chemistry, Pharmacology +9

Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis

Bernard Sadzot, Jay M. Baraban, Richard A. Glennon et al. · Psychopharmacology · 1989 · 130 citations

Medicine, Neuroscience, Pharmacology +8

Selectivity of serotonergic drugs for multiple brain serotonin receptors

Milt Titeler, Robert A. Lyon, Katharine H. Davis et al. · Biochemical Pharmacology · 1987 · 118 citations

Medicine, Neuroscience, Pharmacology +13